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1. Introduction 
Brucella is ǂ-Proteobacteria causing an infectious disease in mammals that could be 
transmitted to humans. Ruminant and swine are prone to be infected by such 
microorganism all over the world, thus acting as a potential reservoir for domestic livestock 
and therefore, affecting humans. Brucella species differ in their hosts’ preference, 
physiological abilities and cell surface structural characteristics. Those affecting domestic 
livestock are B. melitensis (sheep and goats), B. abortus (cattle), B. suis (swine), and B. ovis 
(sheep). Because domestic ruminants and swine are essential to the economy of millions of 
people, particularly in low income countries, brucellosis is a major cause of direct 
economical losses and a major impediment for trade. Moreover, human brucellosis is a 
severe and debilitating disease requiring a prolonged antibiotic treatment and often leaving 
permanent and disabling sequel. Thus, its control and if it possible its eradication are major 
goals of public health programs in affected countries (1,2). 
2. The bacterium 
Brucella belongs to the ǂ- 2 subdivision of the proteobacteria, along with ochrobactrum, 
rhizobium, rhodobacter, agrobacterium, bartonella, and rickettsia. The traditional classification of 
Brucella species is largely based on its preferred hosts. There are six classic pathogens, of 
which four are recognized human zoonoses. The presence of rough or smooth 
lipopolysaccharide is correlated to the virulence of the disease in humans. Two new Brucella 
species, provisionally called Brucella pinnipediae and B. cetaceae, have been isolated from 
marine hosts within the past few years (3,4,). 
Brucella is a monospecific genus that should be termed B. melitensis, and all other species are 
subtypes, with an interspecies homology above 87 percent. The phenotypic differences and 
host preferences can be attributed to various proteomes, as exemplified by specific outer-
membrane protein markers. All Brucella species seem to have arisen from a common 
ancestor to which B. suis biotype 3 shares particular similarity. Although the scientific 
accuracy of this classification cannot be disputed, its practicality has been under scrutiny (5). 
3. Nomenclature and classification  
The Manchester report assumed the paper by Verger et al. on DNA hybridization studies 
and the proposition that all Brucella are just one species, with biovars; it was necessary to 
www.intechopen.com
 
Zoonosis 
 
144 
reclassify Brucella abortus biovar 9 as Brucella melitensis biovar abortus 7, following deletion 
of biovars 7 and 8. It is remarkable that, according to the Manchester nomenclature, all 
‘biovars’ Melitensis 1–3, Abortus 1–7 and Suis 1–5 were assigned to the same level of 
differentiation, irrespective of previous nomenspecies; this is undoubtedly correct and is 
based on genome studies, but misleading for brucellosis epidemiology considering the 
relatedness of nomenspecies with host animals and geographical spreading. Moreover, 
McGillivery et al. (1988) found that the restriction endonuclease profiles produced by BamHI 
from DNA of five Brucella abortus isolates and the reference strain B. abortus biovar 2 were 
very similar. These results reinforced the existence of significant genetic homogeneity in 
Brucella genus. The report also emphasizes the relatedness of genus Brucella with the genera 
Agrobacterium, Phyllobacterium and Rhizobium. De Ley et al. identified B. abortus as a member 
in the ǂ-2 subgroup of Proteobacteria on the basis of 16S rRNA gene sequence comparison 
and Moreno et al. suggested a close phylogenetic relation within the same group as a result 
of studying the composition of Brucella lipid A; later, Corbel published dendrogram 
considered it as serologically related (Yersinia enterocolitica O: 9, Yersinia pseudotuberculosis, 
Salmonella typhimurium, Vibrio cholerae, Francisella tularensis, Escherichia coli O: 157, 
Pseudomonas putida, Rickettsia prowazekii) (6,7). 
4. Genetics of the Brucella 
Classic genetic studies of Brucella was begun by spontaneous mutants in the early 20th century 
.The most widely studied spontaneous mutants are vaccine strains, such as B. melitensis Rev 1, 
B. abortus strain 19 and recently B. abortus strain RB51. The classic genetic studies are focused 
on phenotypic appearance, stability, metabolism and virulence of mutant colonies. 
Smoothness and roughness of the colonies usually attribute to high and low virulence of B. 
abortus, B. suis, and B. melitensis. Mutation causing changes in appearance of the colonies 
(smoothness → roughness) usually decreases the virulence of these species and decreases or 
eliminates the stimulation of antibodies to the O antigen in animal hosts. B. abortus strain RB51 
illustrates this well, it is a rough strain which is highly attenuated and does not induce anti-O 
antibodies. The Brucella genome has a GC content of approximately 58%. B. melitensis, B. 
abortus, B. ovis, B. neotomae, and B. suis biovar 1, each has two chromosomes of 2,100 kb and 
1,150 kb. However, B. suis biovar 2 and 4 have two chromosomes of 1.85 Mb and 1.35 Mb, and 
B. suis biovar 3 has only one chromosome with a size of 3.1 Mb. These differences in size and 
number of chromosomes can be explained by rearrangements resulting from homologous 
recombination at chromosome regions containing the three rrn genes. The DNA sequences 
amongst different Brucella species share more than 90% homology. According to the present 
taxonomy and phylogeny based on 16S RNA, the classic 6 species belong to a single species. 
This fact has been used to propose that the genus Brucella contains only a single species B. 
melitensis, and that the remaining classic species be considered biovars .Insertion sequences (IS) 
are discrete segments of DNA that can transpose from one genomic site to another and 
promote genetic rearrangements. Insertion sequences are found on both chromosomes of 
Brucella. All Brucella species contain approximately 8-35 copies of an insertion sequence 
denominated IS711 (also known as IS6501). The position and copy number of this insertion 
sequence seems to vary in different species, a characteristic which can be used to differentiate 
them. For example, the wboA gene in B. abortus RB51 is disrupted by an IS711-like element. 
Based on this, a PCR assay has been developed to distinguish strain RB51 from other Brucella 
spp. and strains including its parent strain 2308. Many PCR assays based on gene differences 
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have been developed to detect or differentiate various Brucella strains. There are more than 50 
Brucella genes with a variety of functions listed in GenBank. For example, GenBank includes 
genes that encode the chaperones such as dnaK, groEL, and groES. Both 16S RNA and 23S 
RNA DNA sequences of Brucella are found in GenBank. No resident plasmids have been 
found in Brucella. However, several plasmids have been shown to be able to replicate in the 
Brucella (8,9). 
5. Antigenic composition 
A substantial number of antigenic components of Brucella have been characterized. 
However, the lipopolysaccharide constituents of the cell wall in Brucella species cause the 
antibody to response to such species. Brucella devoid of the o-polysaccharide (O-PS) are 
termed rough or “R” because their colonial surface contrasts with the glistening, smooth 
aspect of those carrying S-LPS. They can naturally be members of the R Brucella species (B. 
canis and B. ovis) or mutants derived from the S Brucella species (B. melitensis, B. abortus and 
B. suis)(18,19,20). Cultures of S Brucella spontaneously dissociate to generate mixtures of S 
and R colonies, the latter is formed by R mutants. Owing to their lack of antigenic O-PS, true 
R mutants neither induce anti O-PS antibodies nor react with antibodies of this specificity. 
They also show other outer membrane topology and physiological changes due to lack of O-
PS. Manifestations of these changes are the uptake of crystal violet, the auto agglutination in 
acryflavin solutions and the sensitivity to Brucella phages specific for the R species. Since the 
S → R dissociation occurs spontaneously with a frequency that depends on the strain and 
growth conditions, repeated in vivo or in vitro passage has been used to obtain R- mutant 
strain for vaccines production. The B. abortus 45/20 and RB51 strains were developed in this 
way. Alternatively, R mutants can be generated by new molecular genetics techniques such 
as transposon mutagenesis or deletion of genes involved in S-LPS biosynthesis.  It has been 
known for a long time that Brucella R mutants are attenuated spontaneously. This 
attenuation has been ascribed to the increase in both the antibody independent complement 
activation and the sensitivity to polycationic bactericidal peptides. In addition, R mutants 
display altered attachment to cells. Moreover, since the S Brucella are intracellular parasites 
able to alter constitutively intracellular trafficking (i.e. the one followed by inert particles or 
non-virulent Brucella), other factors related to the interplay of R mutant is the importance of 
the host cell, an aspect that has not been investigated so far. The outer membrane topology 
of rough mutants is altered LPS acylation patterns and could be relevant in this regard 
(4,21,22). The structure of S-LPS content of Brucella is known in part. According to nuclear 
magnetic resonance studies, the O-PS is a homopolymer of N-formyl-perosamine either 
exclusively in ǂ-(1-2) linkages (for example in B. abortus biotype 1) or in ǂ- (1-2) plus ǂ- (1-3) 
in a ≥ 4:1 proportion (4:1 in B. melitensis biotype 1). These O-PSs carry three basic types of 
overlapping epitopes: C (common to all chemical types of Brucella O-PS), M (present in those 
O-PS with ǂ (1-3) linkages) and A (present in those O-PS with no ǂ (1-3) linkages or with a 
proportion of ǂ- (1-2) to ǂ- (1-3) linkages higher than 4:1). Nuclear magnetic resonance 
studies also show that the S-LPS of Yersinia enterocolitica O:9 carries a homopolymer of N-
formyl-perosamine in ǂ- (1-2) linkages and, accordingly, it should be identical to O-PS  
such as those of the B. abortus biotype 1. It might be, however, that some aspect of these  
structures has escaped the nuclear magnetic resonance analyses because, whereas  
some monoclonal antibodies of O-PS specificity react equally with S Brucella and Y.  
enterocolitica O:9 (Cyb epitopes), others recognize epitopes common to all S Brucella but not  
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to Y. enterocolitica O:9 (Cb epitopes), strongly suggests subtle structural differences 
(4,23,24,25). The structure of the LPS core in Brucella is largely unknown and qualitative 
studies show 3-deoxy-D-manno-2- octulosonic acid, mannose, glucose, glucosamine and 
quinovosamine as the main sugars. The synthesis of LPS in Brucella is largely unknown but 
the genetic evidence available is fully consistent with a mechanism similar to that existing in 
some of the best studied gram-negative bacteria. First, lipid A is synthesized on the inner 
face of the cytoplasmic membrane. Second, through the sequential action of 
glycosyltransferases, sugars are added to lipid A until the core oligosaccharide is completed. 
These two pathways are intermingled since two 3-deoxy-D-manno- 2-octulosonate residues 
are added before lipid A synthesis is finished. On the contrary, the O-PS is synthesized in an 
independent pathway and, once its biosynthesis is carried through, it is linked to the 
acceptor sugar of the completed lipid A-core (19,24,25). Depending on the particular O-PS, 
there are three known types of mechanisms of synthesis, and that of Brucella belongs to the 
so-called ABC transporter-dependent (or wzy-independent) type. In this pathway, a lipid 
carrier (undecaprenol pyrophosphate) on the cytoplasmic side of the membrane is first 
primed with an amino sugar by the WecA protein. Then, O-PS sugar units are inserted 
successively at the non-reducing end (i.e. the “tip” of the growing polysaccharide) by 
glycosyltransferases .Finally, the ABC proteins translocate the amino sugar-O-PS (possibly 
still linked to the undecaprenol) to the periplasmic side of the membrane where a ligase 
(WaaL) binds the amino sugar-O-PS to the completed lipid A-core. Thus, when the synthesis 
of the core is blocked, the O-PS is generally not incorporated to the LPS (25). In addition to 
the lipid A, core, and O-PS pathways, there are subsidiary pathways that provide the 
necessary nucleotide-sugar precursors. Some of them are exclusive to LPS biosynthesis 
whereas others are housekeeping pathways. The more recent nomenclature for the genes 
coding for the enzymes of LPS synthesis uses four letters:1 (i), lpx* for those involved in the 
early steps of lipid A synthesis; (ii), wa** for those involved in the late steps of lipid A 
synthesis, in core synthesis and in the ligation of the amino sugar-O-PS to the lipid A-core 
(waaL); (iii), wb** for those involved in the OP-S synthesis; and (iv), wz** for those involved 
in OP-S processing (for example, wzm/wzt are the genes coding for the ABC transporters 
such as those acting on Brucella OP-S). The genes coding for the enzymes belonging to the 
precursor pathways follow a conventional nomenclature (for example man* for mannose 
biosynthesis, per for perosamine synthetase, etc.) even though they functionally belong to 
LPS pathways. Sometimes there are two different genes for the same enzymatic function as 
there can be two pathways for the same sugar when it is present in both the core or the O-PS 
and, in this case, sub-indexes are used (for example, manBcore and manBOAg for the 
phosphomannomutases of core and O-PS [O Antigen] mannose synthesis). At least sixteen 
genes have been proven to be involved in Brucella LPS synthesis by analysis of the 
corresponding mutants and, as in many bacteria, most of the O-PS ones are clustered in a 
region (wbk) region. Although mutations in some genes outside wbk also bring about an R 
phenotype, their assignation to the core or O-PS pathways is less clear. As judged by the 
analyses derived from the complete sequence of the B. melitensis and B. suis genomes, genes 
encoding for LPS in Brucella are scattered in chromosomes with the exception of the wbk 
region (26). R strains of B. melitensis, B. abortus and B. suis should result from mutations in 
some wa** genes (including WaaL), in all wb** genes, in the wzm/wzt genes, and in genes of 
the pathways that lead to precursors of core and O-PS sugars (for example manBcore and per, 
respectively). But for the absence of an O-PS linked to the remaining LPS molecule, it can be 
predicted that not all these mutants are equivalent and they can be hypothetically grouped 
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as follows: (i), R mutants have a complete lipid A-core plus a cytoplasmic O-PS, the 
incorporation of which to the LPS is blocked (at least the wzm/wzt and possibly the WaaL 
mutants); (ii), R mutants have a complete lipid A-core but no O-PS (mutants in wb** 
glycosyltransferases, in wecA, and in genes coding for enzymes necessary to synthesise some 
precursors, such as manBOAg, gmd and per) and (iii), R mutants have progressive 
deficiencies in the core and that may or may not accumulate cytoplasmic O-PS (mutants in 
some wa** genes and in some precursor genes such as manBcore). Mutants of each of these 
three groups have in fact been described, and the question then arises as to what extent they 
are equivalent in attenuation and immunizing abilities (27,28,29,30). Numerous outer and 
inner membranes, cytoplasmic, and periplasmic antigenic proteins have also been 
characterized. Some are recognized by the immune system during infection and are 
potentially useful in diagnostic tests. Hitherto, tests based on such antigens have suffered 
from low sensitivity as infected persons tend to develop a much less consistent response to 
individual protein antigens than to LPS. Thus, tests such as immuno-blotting against whole-
cell extracts may have some advantages over more quantitative tests that employ purified 
individual antigens. Recently, ribosomal proteins have reemerged as immunologically 
important components. Interest in these, first arose more than 20 years ago when crude 
ribosomal preparations were demonstrated to stimulate both antibody and cell-mediated 
responses and to confer protection against challenge with Brucella. However, the individual 
components responsible for such activity were not identified until recently. It has been 
established that the L7/L12 ribosomal proteins are important in stimulating cell-mediated 
responses. They elicit delayed hypersensivity responses as components of brucellins, and as 
fusion proteins, they have been shown to stimulate protective responses to Brucella. They 
appear to have potential as candidate vaccine components (31,32). 
Bacterial pathogens that maintain long-term residence within host phagocytes probably 
express a variety of genes to help them adapt to the harsh environmental conditions of pH, 
nutrition deprivation, ROIs, and reactive nitrogen intermediates (RNIs) as well as lysosomal 
enzymes encountered within the phagosome .Prominent among these responses is the 
induction of heat shock proteins, suggesting that considerable protein misfolding and 
damage occurs within this compartment. However, the role of these proteins in Brucella 
pathogenesis was uncertain. B. abortus Lon transposon mutants were attenuated in BALB/c 
resident peritoneal macrophages but persistent in BALB/c mice except for a minor 
attenuation at 1 week postinfection, suggesting that Lon protease is important for Brucella 
survival during early infection. B. suis dnaK insertional mutants, defective in a member of 
the Hsp70 family, were attenuated in the human macrophagic cell line, U937. B. abortus htrA 
deletion mutants, deficient in a serine protease called high temperature- requirement A 
protein, have been considered to be attenuated in vitro and in vivo, but a recent report 
suggests that htrA mutants were in fact htrA cycL double deletion mutants. An additional 
report suggests that a B.melitensis authentic htrA deletion mutant was not attenuated in 
goats, suggesting that HtrA is not involved in Brucella pathogenesis. Also, the B. suis clpA 
deletion mutant was not attenuated in vitro or in vivo. Taken together, these reports suggest 
that not all heat shock proteins are critical to Brucella pathogenesis or that redundant 
function of heat shock proteins will compromise the functional deficiency caused by the loss 
of one heat shock protein (33,34,35,36). 
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6. Virulence 
The basis for the virulence of Brucella can be attributed to the ability of these bacteria to 
escape the host defense mechanisms and to survive and replicate within the host cells.  
Attempts to identify Brucella virulence factors have been made. The first studies reported 
that intracellular multiplication of Brucella was attributable to erythritol .Virulent Brucellae 
are capable of invading and residing in professional phagocytes, such as macrophages, as 
well as non-phagocytic cells. The mechanism of attachment and entry into these cells by 
Brucella has yet to be clearly elucidated. Virulence mechanisms identified so far is associated 
with the ability to reside within phagocytic and/or non-phagocytic cells are as follows: the 
ability to inhibit phagolysosome fusion, degranulation and activation of the myelo-
peroxidase-halide system, and the production of tumor necrosis factor (37,38). 
In both phagocytic and non-phagocytic cells, Brucella has the ability to replicate within 
membrane-bound compartments. In non-phagocytic cells, such as HeLa cells, virulent B 
.abortus 2308 has been documented to replicate in the endoplasmic reticulum by utilizing the 
auto phagic machinery of the HeLa cell. In professional phagocytes, the membrane-bound 
compartment within which virulent Brucella organisms can replicate is the phagosome. By 
some unknown mechanism, Brucella is able to block phagolysosome fusion. It is now 
thought that the production of adenine and guanine monophosphate can inhibit 
phagolysosome fusion. The ability to produce these compounds is therefore considered as 
virulence factor of Brucella. In contrast, attenuated strains of Brucella are unable to prevent 
such fusion and are thereby destroyed by the lysosomal contents. Research on intracellular 
survival and replication of Brucella within professional phagocytes has mainly focused on 
macrophages (39,40). Survival within macrophages is apparently associated with the 
production of many different proteins. These proteins tend to be stress induced proteins 
such as heat shock or acid-induced proteins. They include 17, 24, 28, 60, and 62 KD proteins . 
Two of these proteins, the 17 and 28 KD proteins, seem to be induced only during 
intracellular cohabitation of Brucella with macrophages (41,42). HtrA, another stress-induced 
protein, has been examined for its possible role in virulence and intracellular survival. Using 
deletion mutants, HtrA has been shown to be involved in inducing a granulomatous 
reaction and thus reduces the levels of infection during the early phase of infection (murine 
model). However, this does not result in reduced levels in the later phases of infection. In 
fact, overall, htrA-deficient mutants produce spleenic bacterial loads comparable to their 11 
wild-type counterparts. RecA mutants produce similar results as htrA mutants in early- and 
late-phase spleenic load (43).Two other types of proteins that have been put forth as possible 
virulence factors are siderophores and Cu-Zn superoxide dismutase (Cu-Zn SOD). Iron-
sequestration by siderophores may be an integral virulence factor in intracellular survival of 
Brucella species. Low levels of iron in vivo aid the host's ability to restrict microbial growth. 
Brucella species do carry iron-sequestering proteins and other siderophores, but their role in 
pathogenesis has not been clearly elucidated. Cu-Zn SOD may play a significant role in the 
early phase of intracellular infection, but contradictory results have been reported. Further 
studies are needed before the role of Cu-Zn SOD as a virulence factor of intracellular 
survival of Brucella can be accurately assessed (33,44). An auxotrophic mutation encoding 
for an essential enzyme (5’-phosphoribosyl-5-amino-4-imidazole carboxylase) necessary for 
the de novo synthesis of purines has been demonstrated to be essential for the intracellular 
www.intechopen.com
 
Brucellosis Vaccines: An Overview 
 
149 
survival of B. melitensis. Deletion of the gene, purE, encoding this enzyme in virulent B. 
melitensis drastically reduced its ability to survive within macrophages and demonstrated 
attenuated behavior in mice and goats. Recently, a two-component regulatory system has 
been discovered in B. abortus. The Brucella virulence related proteins (Bvr) system consists of 
a regulatory (BvrR) and a sensory protein (BvrS). This regulatory system, BvrR-BvrS, may 
play a critical role in the ability of B.abortus to invade and multiply within cells. BvrR-
deficient mutants were obtained by transposon mutagenesis. Morphologically, these 
mutants produced smooth-type LPS (45). They were found to be increasingly sensitive to 
polycations surfactants and showed decreased in vivo replication and persistence in mouse 
spleens. This occurred even though no obvious 12 growth defects could be detected in the 
mutants in vivo. Complementation with the bvrR gene restores resistance to polycations and 
partially restored the ability of these mutants to multiply intracellularly. The results further 
suggest that restoration of full virulence requires both components of the regulatory system 
to be intact. Interestingly, LPS core and lipid A are known to be involved in polycationic 
resistance. Therefore, it is possible that these LPS features involved in polycationic 
resistance are under the BvrR-BvrS regulatory system. Analysis at the DNA level of bvrR 
and bvrS genes revealed that they are highly homologous to other regulatory systems being 
found within symbiotic plant pathogens such as Rhizobium meliloti (ChvI-ExoS system) and 
Agrobacterium tumefaciens (ChvI-ChvG system). It has been established that B. abortus, R. 
meliloti, and A. tumefaciens are phylogenetically related. Therefore, this suggests that the 
BvrR-BvrS system co-evolved with the other two systems listed above to aid in the ability of 
Brucella to survive intracellularly (22,46). Recently in B .suis, genes encoding a type IV 
secretion system homologous to the Agrobacterium tumefaciens VirB and Bordatella perutussis 
Pt1 systems have been identified to be essential for the intracellular survival in HeLa cells 
and human macrophages. Further research is needed to clearly understand the actual role of 
this secretion system in the virulence of Brucella species (47). At present, there is no evidence 
to support a secretion system within Brucella. If Brucella is capable of secreting, it is probably 
in very small amounts. Non-protein components of Brucella may also contribute to its ability 
to survive within cells. One such cellular component, lipopolysaccharide (LPS) will be 
discussed in the section below (46,47). 
The LPS of smooth strains of Brucella are comprised of a lipid A molecule, fatty acids, a core 
region, and a polysaccharide O-side chain. This O-side chain is made from a homopolymer 
of perosamine and is found on the surface of smooth strains, while rough organisms lack 
this chain on their LPS. Smooth Brucellae are able to survive intracellularly as compared to 
their rough counterparts. Therefore, smooth lipopolysaccharide (S-LPS) probably plays a 
significant role in pathogenesis. The simple explanation of rough versus smooth 
morphology and virulence, however, does not explain how naturally occurring rough 
species B. ovis and B. canis retain their virulence. Using Tn5 transposon mutagenesis, several 
genes necessary for the synthesis of S-LPS have recently been identified. Both in vitro and in 
vivo studies with the rough mutants derived from the deletion of these genes clearly 
established that S-LPS is necessary for efficient intracellular survival and virulence of B. 
melitensis, B. abortus, and B. suis. B. abortus S-LPS is 100 times less potent than that of E. coli 
and Salmonella in inducing TNF from macrophages as well as oxidative metabolism and 
lysozyme release by human neutrophils. This feature of S-LPS has been proposed to 
contribute to the survival of B. abortus within phagocytic cells. In addition, Brucella S-LPS is 
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not susceptible to the actions of polycationic molecules, suggesting that smooth Brucella can 
resist the cationic bactericidal peptides of the phagocytes. S-LPS has also been found to 
confer anti-phagocytic properties to Brucella and does not activate the alternate pathway of 
the complement cascade (37,48,49).  
7. Brucella vaccines 
7.1 Live, attenuated vaccines 
Both killed and live, attenuated vaccines have been examined for their potential role in the 
control and eradication of brucellosis in cattle, goats, and swine. Live, attenuated vaccines 
carry several advantages over their killed counterparts. First, immunity derived from their 
use tends to be cell-mediated and long lasting. Also, as they are administered live, the 
organism is allowed to replicate within the host, thus making them less expensive. 
However, some live, attenuated vaccines may cause abortion in pregnant females and 
therefore their use is often relegated to males and non-gravid females.  
The two main live, attenuated vaccines used in the control of B. abortus infection in cattle are 
B. abortus strain 19 and B. abortus strain RB51. A brief discussion of each, plus the use of B. 
melitensis strain Rev. 1 in goats, follows (48,50). 
7.2 Killed vaccines 
Killed vaccines can offer protection to a disease while still retaining safety for those animals 
that are young, immuno-suppressed, or pregnant. Over the years, a variety of killed 
vaccines have been developed for protection against brucellosis. They have had limited 
success. None have approached the protection status afforded by the live, attenuated 
vaccines. Examples of vaccines in this category are B. abortus strain 45/20 and B. melitensis 
H38. In addition to the lack of sufficient protection in the face of challenge, killed vaccines 
such as 45/20 and H38 can induce persistent antibody titers that can interfere with common 
serological tests used (51,52,53). 
7.3 Brucella abortus vaccines 
7.3.1 B. abortus strain 19 
Brucella abortus strain 19 (S19) is a smooth but attenuated strain. The molecular basis for the 
attenuation is not known. The strain S19 has been shown to contain a deletion in the 
erythritol catabolic genes rendering it sensitive to erythritol. However, such a deletion in 
virulent strains has been shown not to result in attenuation. Prior to the introduction of 
vaccine strain RB51 in 1996, B. abortus S19 was known to be the official vaccine strain. The 
strain S19 was quite effective in protecting cattle against subsequent infection with virulent 
strains of B. abortus (54). However, S19 did have several problems that restricted its use 
within the cattle. During protection studies, it was discovered that S19, when given to adult 
cattle (>1yr), often caused persistent titers which could not be distinguished from titers 
resulting from a natural infection using standard serological tests. The tests like a plate 
agglutination test, complement fixation (CFT), and tube agglutination tests can only detect 
the presence of antibodies against O-antigens. This directly undermined the brucellosis 
eradication program that was dependent on a test and slaughter strategy to reduce numbers 
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of infected cattle within the United States. Persistent antibodies could be detected for up to 
10-11 months post vaccination when vaccinating adult cattle with the standard dose (3 × 1010 
CFU). Although a rare finding, even some calves vaccinated S19 produced persistent 
antibodies (55,56). Use of S19 in pregnant cattle also resulted in abortions. Even when a 
reduced dose of S19 (1/20-1/100 of the standard dose) was used to vaccinate pregnant 
cattle, abortions in post-inoculation were still observed, although this reduced dose 
appeared to be less abortigenic (57,58). The use of the reduced dose vaccine did not 
eliminate the problem of persistent titers (51,59,60). In fact, these titers lasted about the same 
amount of time as the full dose (60). For this reason, Erasmus and Erasmus recommended 
that vaccination of adults with the reduced dose of S19 be relegated to herds heavily 
infected with B. abortus. As a result of the overwhelming experimental evidence, S19 was 
designated for use as a calf hood vaccine (4 to 12 month of age) (60). Calf hood vaccination 
with S19 is not completely without side effects. As with all other brucellosis vaccines, S19 
cannot be administered to bulls or bull calves due to the resulting persistent orchitis (61). 
There have also been reports of an arthropathy (gonitis) linked to vaccination of female 
calves with S19. Immunological studies by Wyn-Jones and colleagues indicated the presence 
of B. abortus strain S19 antigenic material within the cells of the stifle, synovial membrane 
and the drainage lymph nodes (54). With the discovery of B. abortus strain RB51, the benefits 
of S19 vaccination diminished and RB51 replaced S19 as the official vaccine for the 
brucellosis eradication program. The use of S19 has also raised concerns about human 
exposure to brucellosis vaccines. 
There have been several reports of illness following accidental self-inoculation with the S19 
vaccine (54,62). This stresses the importance of safe-handling practices when vaccinating 
herds for brucellosis using the S19 vaccine. It also led investigators to try and develop a 
more efficacious cattle vaccine that would also be safer in terms of potential human 
exposure (62,63,64). 
7.3.2 B. abortus strain RB51 
The use of B. abortus strain RB51 was approved to be the official strain employed to 
manufacture calf hood vaccine for protection against brucellosis in 1996. Vaccine strain RB51 
is a stable, rifampin-resistant, and derived from rough mutant of B. abortus 2308. It was 
derived by serial passage of parental strain 2308 on trypticase soy agar supplemented with 
varying concentrations of rifampin and penicillin. Colonies of RB51 are rough in 
morphology as indicated by their ability to absorb crystal violet as well as auto-agglutinate 
when in suspension. The LPS of RB51 is deficient in O-side chain, unlike its parental strain 
2308. Metabolically, RB51 shares the ability to use erythritol with strain 2308 and RB51 has 
proven to be an extremely stable rough mutant of B. abortus. Its stability and efficacy have 
been shown in vitro and in vivo (65,66). Like the strain S19 vaccine, calves must be 
vaccinated with strain RB51 between the ages of 4-12 months of age with the calf dose (1.0-
3.4 ×1010  CFU) and in high risk area animals receive the vaccine after 12 month of age (67). 
Advantages of RB51 over other vaccines for protection against bovine brucellosis are 
numerous. It does not produce any clinical signs post-vaccination, nor does it produce a 
local reaction at the site of injection (65). It is rapidly cleared from the bloodstream, as early 
as 2 weeks after post-inoculation. It is not shed in the nasal secretions, saliva, or urine. 
Therefore, the organism appears to be unable to spread from vaccinated to non-vaccinated 
animals through these routes. In immuno-suppressed animals, no recrudescence of infection 
has been documented. In addition, vaccination with RB51 affords a high level of protection, 
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characterized by good cell mediated immunity. In one study, vaccination of cattle at least 
one year prior to mating induced 100% protection against abortion caused by exposure to 
field conditions of high and low brucellosis levels .The use of RB51 has also helped clear up 
the issue of Brucella-positive/"reactor" animals. Since RB51 lacks O-side chain, vaccination 
with the strain (unlike strain 19) produces no antibodies to O-side chain. This is particularly 
advantageous because all of the diagnostic tests used to screen for brucellosis in herds are 
directed toward the detection of O-antibodies in the serum or milk. Cattle vaccinated with 
RB51 are negative on all subsequent serological tests, including agar gel diffusion test. This 
lack of interfering antibodies is even true in the face of calf hood vaccination with strain 19 
and subsequent adult vaccination with RB51 (68). 
Although, sera from RB51 vaccinated cattle do not respond to standard diagnostic tests, they 
do contain antibodies that react to a dot-blot ELISA containing RB51 antigen (65). As these 
antigens are common to both RB51 and 2308, the dot-blot ELISA test cannot differentiate 
between vaccinated and infected animals; it is, therefore, relegated to assessing the humoral, 
non-protective immune response of cattle post-inoculation (69). In addition, there are two 
molecular methodologies that may be used to differentiate RB51 from other isolates: pulse 
field gel electrophoresis (PFGE) and polymerase chain reaction (PCR). RB51 possesses a 
unique fingerprint using the pulsed-field gel electrophoresis patterns of genomic DNA 
digested with restrictive endonuclease Xba I. The fingerprint of RB51 contains a unique band 
at 104 kb, as opposed to a 109-kb fragment within genomic DNA samples of B. abortus 
isolates from naturally infected cattle, bison, and elk (70). In addition, there is a specific PCR 
test that can differentiate RB51 isolates from all other Brucella isolates tested. This PCR 
method is based on the interruption of the wboA gene by an insertion element (IS711), a 
unique mutation present only in RB51 (71). In a murine model, B. abortus strain RB51 has 
been shown to confer protection against challenge with B. melitensis, B. suis, and B. ovis. 
However, in rams this vaccine did not induce protection against B. ovis challenge. Field 
trials indicate that B. abortus strain RB51 is also protective against swine brucellosis. 
In addition to domesticated species, B. abortus strain RB51 has also been used to vaccinate 
wild animals such as bison and elk. Oral vaccination of mice and cattle with RB51 has been 
shown to be effective in inducing protective immune responses. These results are 
encouraging and highlight the feasibility of oral vaccination of wild life on a large scale. 
RB51 may appear to be a safe vaccine with respect to human exposure (72,73).  
7.4 Brucella melitensis vaccines 
7.4.1 B. melitensis Rev. 1. 
B. melitensis Rev. 1 (Rev1) is currently the only approved vaccine available for protection 
against B. melitensis infection. In 1957, a smooth attenuated strain of B. melitensis was 
isolated from a streptomycin-dependent population that had been grown in a streptomycin 
deficient medium. In experimental challenge trials in goats, this strain was found to induce 
significant protection against the virulent challenge strain without shedding the organism. 
The organism was later designated B. melitensis Rev. 1. Use of the Rev1 vaccine has both 
advantages and disadvantages. Vaccination with Rev1 induces significant protection in 
sheep and goats. Rev1 has been found to be much more protective in goats and sheep 
challenged with virulent B. melitensis than those animals vaccinated with S19. The Rev1 
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vaccine does have some disadvantages. It can cause abortions if used in pregnant animals. 
Vaccination with Rev1 can result in persisting agglutinins that can interfere with various 
serological diagnostic tests. Rev1 is pathogenic to humans via aerosol exposure or self-
inoculation causing generalized brucellosis in affected individuals. Like all other Brucella 
vaccines, Rev1 can cause local hypersensitivity reactions in cases of accidental inoculation 
(12,74,75,76,77,78). 
8. Brucella R mutants for vaccine studies 
8.1 B. abortus 45/20 
This R vaccine was obtained after twenty passages in guinea pigs of a field isolate (B. abortus 
strain 45) in 1938. However, the original 45/20 strain was reported to revert to S pathogenic 
forms when injected into cattle. Alton reports of experiments with several 45/20 stocks 
which, after repeated passages in guinea pigs, showed either S-intermediate and R colonies 
or only R forms depending on the origin of the stocks. This suggests that the original strain 
contained in fact several different clones so that the S-intermediate ones were selected when 
injected into cattle. Also, it seems likely that different laboratory variants of this strain have 
coexisted for years. The genetic defects in this strain are unknown and the vaccine is not 
presently marketed (65,79).  
8.2 B. abortus RB51 
 Strain RB51 is a spontaneous R mutant selected after repeated in vitro passages of B. abortus 
2308 on media containing rifampin and penicillin. Selection was performed using crystal 
violet and acryflavin tests. RB51 carries an IS711 spontaneously inserted into wboA 
(putatively coding for a glycosyltransferase). However, a wboA transposon mutant obtained 
from strain 2308 is not as attenuated as RB51 and the protection afforded by wboA mutant 
vaccines in mice is better than that provided by RB51, which shows that RB51 carries 
additional and unknown defects. In the complete sequence of B. melitensis, B. suis and B. 
abortus genomes (an annotated B. abortus complete sequence is not available) wboA maps 
outside of the main wbk* O-PS genetic region. RB51 accumulates small amounts of O-PS. 
This is noteworthy because, accepting that the current model of the B. abortus LPS structure 
is correct, mutation in a wb** gene should prevent O-PS synthesis. Complementation of 
RB51 with wboA increases O-chain expression but does not restore the S phenotype 
suggesting that other LPS genes are affected. In addition, although sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis (SDS-PAGE) migration patterns have been 
interpreted to mean that RB51 carries a LPS with a complete core, chemical analyses showed 
that this R-LPS contains 2.5 times less mannose than the B. abortus RA1 wboA mutant. The 
presence of additional mutations in genes of strain RB51 are not involved in LPS synthesis 
and cannot be excluded either (80,81). On the contrary to 45/20, RB51 is stable and it is 
currently being used in some countries instead of S19. Although it should show very low or 
no virulence in humans, there is little information on this point and there has been at least 
one case of RB51 infection in a veterinarian demonstrated by bacteriological isolation and 
typing of the strain. It has to be stressed that RB51 is resistant to rifampin, an antibiotic 
currently used in the groups of brucellosis patients that cannot be treated with streptomycin 
(pregnant women, children of young age, and endocarditis and neurobrucellosis cases) (34). 
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 RB51 has been used as the starting strain in two genetic manipulations. First, the wboA 
defect has been complemented with a functional wboA gene to generate strain RB51Wboa. 
This strain keeps the R phenotype manifested in the crystal violet and acryflavin tests, but 
expresses increased amounts of O-PS which by immuno-electron microscopy seems to be 
accumulated in the cytoplasm. However, at least part of this O-PS may be linked to a lipid to 
give an immunogenic form because it migrates in SDS-PAGE and vaccination of mice with 
RB51WboA elicits IgG antibodies of at least C specificity. Second, the Brucella Cu/Zn 
superoxide dismutase gene has been introduced in RB51 to obtain strain RB51SOD which 
over expresses (tenfold) this protein. The aim of this manipulation is to increase the 
expression of a Brucella antigen and a possible virulence factor on the RB51 background 
(33,82,83). 
8.3 wboA mutants other than RB51  
Mutants in this putative glycosyltransferase gene have been obtained from B. melitensis 16M 
and B. suis 2579 by allelic exchange to generate the strains VTRM1 and VTRS1, respectively. 
Both are kanamycin resistant since they carry a Tn5 element. Although, it was originally 
named rfbU, blast analysis of the Salmonella typhi RfbU prototype against the B. melitensis 
genome shows the highest similarity (E value 1e–16) with WbkA, and more recently the gene 
has been renamed wboA (E value for RfbU versus WboA is only 2e–04). The VTRM1 and 
VTRS1 mutants are stable in mice, lack reactivity with monoclonal antibodies of C 
specificity and have an R phenotype but they have not been tested for the absence of core 
defects or expression of cytoplasmic O-PS (84,85,86). 
8.4 Mutants in the wbk region 
Several mutants in this cluster of O polysaccharide genes have been describe, and two have 
been analyzed as vaccines. B. abortus 2.17 and B. abortus 9.49 have been obtained from B. 
abortus 2308 by transposon mutagenesis and selection for polymyxin B sensitivity, and they 
carry the Tn5 insert (they are kanamycin resistant) in wbkA and per, respectively. Both are 
resistant to the S Brucella specific phages, sensitive to the R Brucella specific R/C phage and 
positive in the crystal violet and acryflavin tests and do not express O-PS. As judged by the 
electrophoretic mobility and the reactivity with monoclonal antibodies specific for the inner 
and outer core epitopes, the R-LPS of both mutants keeps an intact core oligosaccharide, 
which is consistent with the position of wbkA in the major O-PS genetic region and the 
putative role of Per. 4.6. Mutants in genes affecting the LPS core structure (27,28,29).  
8.5 B. abortus B2211 pgm  
This mutant carries a gentamicin-resistance non polar cassette in the pgm 
(phosphoglucomutase) gene of B. abortus 2308. It is resistant to the S-Brucella specific Tb 
phage and carries R-LPS as judged by SDS-PAGE analysis. The central role of this enzyme in 
the synthesis of hexoses derived from glucose makes pleiotropic effects on the synthesis of 
oligo- and polysaccharides likely and, at least, the pgm mutant is also blocked in the 
synthesisof the periplasmic ǃ(1,2) cyclic glucans . Mutation in the homologous gene of B. 
melitensis causes a core defect as judged by the electrophoretic mobility in SDS-PAGE of its 
R-LPS (30,87,88)).  
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8.6 B. abortus mutant 80.16 wa** 
This is a mutant in a putative glycosyltransferase gene involved in core synthesis (hence its 
provisional denomination as wa**) as shown by SDS-PAGE and Western blots with 
monoclonal antibodies to core epitopes. Like B. abortus 9.49, it was obtained by Tn5 
transposon mutagenesis of B. abortus 2308 and selection for polymyxin B sensitivity. This 
mutant is resistant to kanamycin, to the S brucella phages, sensitive to phage R/C and does 
not express O-PS. A remarkable feature of the R-LPS of this mutant is that while keeping a 
fully reactive outer core epitope, it shows a reduced reactivity with monoclonal antibodies 
to the inner core epitope suggestive of a branch in the inner core in which the missing 
sugar(s) would be placed (29).  
8.7 B. abortus manBcore mutants 
Two different mutants in this gene, both from B. abortus 2308, have been described: the rfbK 
mutant and mutant 55.30. 
 The mutated gene (formerly rfbK but manB according to recent nomenclature) putatively 
codes for a phosphomannomutase and is thus predicted to be involved in the synthesis of 
mannose-1-P. Although mannose-1-P is a precursor of perosamine (the O-PS sugar), the 
mutated gene is not homologous to the manB of the wbk region (manBOAg) and its location , 
the lack of reactivity with monoclonal antibodies of outer core specificity and the SDS-PAGE 
profile of the corresponding R-LPS show that it acts as a manBcore. This is consistent with 
the presence of mannose in the core of B. abortus (12,29,89). 
9. Can proteomics help in developing vaccines to protect animals or humans 
against brucellosis? 
The identification of immunogenic proteins will also be a further step towards the 
understanding of the humoral immune response during Brucella infections. Most studies on 
the antigenicity of Brucella proteins are either hampered by the limited number of proteins 
investigated or the complexity of the protein mixtures used. Differences in the seroreactivity 
of various protein classes are well known, e.g. cytoplasmic proteins induce a higher 
antibody response than outer membrane proteins. Additionally, the production of 
antibodies directed against proteins may be host specific, e.g. anti-OMP28 antibodies were 
detected in Brucella infected humans and goats, but not in pigs and cattle (90). 
Immunoproteomics is the approach to identify specific immunogenic proteins in high 
resolution in the wide range of proteins expressed by Brucella. Previous studies of the 
Brucella proteome mainly focused on B. melitensis and the protein map of B. melitensis 16M 
(htpp://www.proteome.scranton.edu) may be used as a reference map for other Brucella 
spp.. However, crucial phenotypic differences responsible for host specificity, virulence, and 
immunogenicity may exist despite the close genetic relatedness within the genus Brucella. 
Five hundred fifty-seven protein spots representing 232 discrete ORFs were identified in B. 
melitensis using 2-D and MALDI-MS. Protein expression profiles of B. melitensis under 
various growth conditions, in wild type and attenuated vaccine strains have also been 
investigated. B. abortus proteomic studies have primarily been directed at the identification 
of virulence factors (Sowa et al., 1992; Lin and Ficht, 1995; Rafie-Kolpin et al., 1996). 
However, only one immunoproteomic study of Brucella has been published so far. In this, 
Teixeira- Gomes et al. (1997a) identified immunogenic proteins of B. ovis (91,92). 
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A lot of experiences have been involved in a comprehensive analysis of the B. melitensis 16M 
proteome, and initial results have been published recently. Previous proteomics studies 
using B. melitensis cells grown under different conditions have been reported, and initial 
work on the B. abortus proteome has been described. A comparative study was conducted 
with B. abortus vaccine strains S19 and RB51 and virulent strain 2308. recently, 
Eschenbrenner et al.  compared the proteome of laboratory-grown strain Rev 1 to that of 
strain 16M by using two-dimensional (2-D) gel electrophoresis and matrix-assisted laser 
desorption/ionization (MALDI)-mass spectrometry (MS) to elucidate differences between 
the protein expression patterns of the two strains. Differentially expressed proteins were 
identified and grouped into three major classes: (i) protein spots unique to either 16M or 
Rev 1, (ii) proteins overexpressed in Rev 1, and (iii) proteins underexpressed in Rev 1 
(93,94). 
Comparative proteome analysis of vaccine strain Rev 1 and virulent strain 16M of B. 
melitensis indicates that the two strains have significant metabolic differences. Differentially 
expressed proteins involved in iron metabolism, sugar transport, lipid metabolism, and 
protein synthesis were identified. The expression of proteins essential for both low and high 
iron availability suggests a misregulated system for iron metabolism and capture, leading to 
possible unnecessary expenditure of energy. This may be a consequence of successive in 
vitro passages of B. melitensis in the presence of streptomycin. It is difficult to state what 
changes were directly or indirectly effected by this stressful growth condition. However, 
one plausible theory is that to compensate for these changes in gene expression, Rev 1 may 
have up-regulated other pathways, such as those involved in the _ oxidation of fatty acids 
and protein synthesis, to generate more reducing equivalents, ultimately for use in the 
production of ATP. These alterations would compensate for the energy loss due to 
misregulation of iron metabolism (72,95). 
Brifly,The proteomes of selected Brucella spp. have been extensively analyzed by utilizing 
current proteomic technology involving 2-DE and MALDI-MS. In B. melitensis, more than 
500 proteins were identified. The rapid and large-scale identification of proteins in this 
organism was accomplished by using the annotated B. melitensis genome which is now 
available in the GenBank. Coupled with new and powerful tools for data analysis, 
differentially expressed proteins were identified and categorized into several classes. A 
global overview of protein expression patterns emerged, thereby facilitating the 
simultaneous analysis of different metabolic pathways in B. melitensis. Such a global 
characterization would not have been possible by using time consuming and traditional 
biochemical approaches. The era of post-genomic technology offers new and exciting 
opportunities to understand the complete biology of different Brucella species (93,95,96). 
Comprehensive proteome maps of all six Brucella species will be generated in order to 
obtain vital information for vaccine development, identification of pathogenicity islands, 
and establishment of host specificity and evolutionary relatedness. 
10. Brucella subunit vaccine 
Different studies have evaluated surface structures and antigens of Brucella as 
immunopotent components to design an efficient brucellosis subunit vaccine. 
Currently subunit vaccines are being considered to develop effective vaccines for human 
which has been evidenced by vaccines currently available against the infections such as 
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meningococcal diseases and influenza. In parallel, subunit vaccines are hot topics in the 
development and design of human brucellosis vaccine. Jacques et al., showed the efficacy of 
Brucella O-polysaccharide-BSA conjugate in protection against Brucella melitensis H38 (97). 
Other studies have been carried out to design subunit vaccines using other components and 
conjugated compounds such as porins and smooth lipopolysaccharide, recombinant 
ribosomal proteins and anti-OPS specific monoclonal antibodies (98, 99, 100, 101). Brucella 
antigens have been applied along with different adjuvants to augment immune responses 
against this organism. 
The latest studies in the field of brucellosis subunit vaccines have been carried out by 
Bhattacharjee et al (102) and Sharifat et al. (103) have evaluated the (Group B Outer 
Membrane Proteins) GBOMP _ B. melitensis strain 16M LPS non-covalent complex to elicit 
the immunity against brucellosis in mice. In order to explore the efficacy of Brucella abortus 
LPS combined with different adjuvants and proteins (as a vaccine candidate) in the 
induction of response as an effective and long-lasting immunity against Brucella, Sharifat et 
al., evaluated and reported the outer membrane vesicles of Neisseria meningitidis serogroup B 
(GBMOMV) as a potent subcutaneous adjuvant and a part of a brucellosis candidate vaccine 
to induce high titres of specific anti-Brucella abortus S99 LPS in animal model. 
The other candidate antigens are Brucella proteins with different cellular locations (Table 1). 
Four proteins are outer membrane proteins. The other nine proteins are located in 
cytoplasm (5 proteins), periplasm (4 proteins), and cytoplasmic membrane (1 protein) (104). 
 
Symbol Protein Description Location 
BLS Brucella lumazine synthase Cytoplasm 
L7/L12 Ribosomal protein L7/L12 Cytoplasm 
P39 sugar-binding 39-kDa protein Periplasm 
Bfr Ferritin:Bacterioferritin Cytoplasm 
Bp26 Periplasmic immunogenic protein Periplasm 
DnaK Molecular chaperone DnaK Cytoplasm 
IalB Invasion protein B Cytoplasmic membrane 
Omp16 Outer membrane protein MotY Outer membrane 
Omp19 Lipoprotein Omp19 Outer membrane 
Omp25 25 kDa outer-membrane immunogenic protein precursor Outer membrane 
Omp31 OmpA-like transmembrane domain Outer membrane 
SodC Cu/Zn superoxide dismutase Periplasm 
SurA Peptidyl-prolyl cis-trans isomerase Periplasm 
Tig Trigger factor Cytoplasm 
Table 1. Brucella proteins studied as sub-unit vaccines  
11. Bioinformatic application and reverse vaccinoloy 
Reverse vaccinology is an emerging vaccine development approach that starts with the 
prediction of vaccine targets using bioinformatics screening of an entire genome of a 
pathogenic organism (105). Vaxign is the first web-based vaccine design program that 
predicts vaccine targets based on reverse vaccinology. The Vaxign computational pipeline 
includes the following features: subcellular localization, topology (transmembrane helices 
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and beta barrel structure), adhesin probability, similarity to other pathogen sequences, 
similarity to host genome sequences (e.g., human or mouse), and MHC class I and II epitope 
predictions. Vaxign has been used to predict Brucella outer membrane proteins (OMP) as 
potential vaccine targets using B. abortus strain 2308 genome as the seed genome (106). 
Vaxign has identified 46 Brucella periplasmic proteins that are conserved in all B. abortus, B. 
melitensis, and B. suis genomes and lack sequence similarity with proteins in human or 
mouse genomes. The values of these proteins for vaccine development also deserve further 
analysis. 
Using the same criteria (sequence conservation and dissimilarity from human or mouse 
proteins), Vaxign has detected approximately 1,000 cytoplasmic proteins. It is impractical to 
individually test this high number of proteins for vaccine development. Considering only 
five cytoplasmic proteins have been experimentally confirmed to be protective antigens out 
of 1,000 conserved cytoplasmic proteins, it is much less likely that cytoplasmic proteins 
serve as protective antigens compared to outer membrane and periplasmic proteins. Vaxign 
also contains an epitope prediction component that can predict MHC class I and II binding 
epitopes (107). The addition of epitope prediction allows further analysis for the existence of 
potential Brucella vaccine targets. 
12. Brucella DNA vaccines 
DNA vaccination is a novel and powerful method of immunization that induces both 
humoral and cellular (Th1 and CTL) immune responses and protection against a variety of 
pathogens (104). Based on the results obtained with DNA vaccines against other pathogenic 
intracellular bacteria, many studies of brucellosis have been conducted (108, 109, 110, 111, 
112, 113, 114). These vaccines induced strong Th1 responses, and some of them conferred 
protection against challenge with B. abortus (108, 110, 112, 113, 114). 
Immunization of BALB/c mice with B. melitensis Omp31 gene cloned in the pCI plasmid 
(pCIOmp31) conferred protection against B. ovis and B. melitensis infection. Mice vaccinated 
with pCIOmp31 developed a very weak humoral response, and in vitro stimulation of their 
splenocytes with recombinant Omp31 did not induced the secretion of gamma interferon. 
Splenocytes from Omp31-vaccinated animals induced a specific cytotoxic-T-lymphocyte 
activity, which leads to the in vitro lysis of Brucella-infected macrophages. pCIOmp31 
immunization elicited mainly CD8_ T cells, which mediate cytotoxicity via perforins, but 
also CD4_ T cells, which mediate lysis via the Fas-FasL pathway. In vivo depletion of T-cell 
subsets showed that the pCIOmp31-induced protection against Brucella infection is 
mediated predominantly by CD8_ T cells, although CD4_T cells also contribute. Our results 
demonstrate that the Omp31 DNA vaccine induces cytotoxic responses that have the 
potential to contribute to protection against Brucella infection. The protective response 
could be related to the induction of CD8_ T cells that eliminate Brucella-infected cells via the 
perforin pathway (115). 
Kurar and Splitter (110) showed that DNA vaccination with the B. abortus ribosomal L7/L12 
gene elicits humoral and cellular immune responses and partial protection. Thus, plasmid 
DNA vaccination may be a successful alternative method for conferring protection against 
Brucella. In addition, a genetic vaccine, by inducing an immune response to a single protein, 
would make possible the development of diagnostic tests that could differentiate vaccinated 
animals from infected animal.  
www.intechopen.com
 
Brucellosis Vaccines: An Overview 
 
159 
Velikovsky et al.,(113) showed that injection of plasmid DNA carrying the Brucella abortus 
lumazine synthase (BLS) gene (pcDNA-BLS) into BALB/c mice elicits both humoral and 
cellular immune responses. Antibodies to the encoded BLS included immunoglobulin G1 
(IgG1) IgG2a, IgG2b, IgG3, and IgM isotypes. Animals injected with pcDNA-BLS exhibited a 
dominance of IgG2a over IgG1. pcDNA-BLS is a good immunogen for the production of 
humoral and cell-mediated responses in mice and is a candidate for use in future studies of 
vaccination against brucellosis. 
Gonzalez-Smith et al (116) showed that Injection of mice with a plasmid DNA carrying the 
gene for superoxide dismutase (pSecTag-SOD) leads to the development of significant 
protection against B. abortus challenge. They also evaluated the effect of delivering IL-2 on 
the efficacy of SOD DNA vaccine by generating a plasmid (pSecTag-SOD-IL2) that codes for 
a secretory fusion protein of SOD and IL-2. Although mice immunized with pSecTag-SOD-
IL2 showed increased resistance to challenge with B. abortus virulent strain 2308, this 
increase was not statistically significant from that of pSecTag-SOD vaccinated mice. These 
results suggest that a SOD DNA vaccine fused to IL2 did not improve protection efficacy 
(116). 
DNA vaccination approaches offer the possibility of inducing both cellular and humoral 
responses. Approaches have varied from use of a whole library from B. abortus (117), 
overcoming the need for prior knowledge and selection of specific antigens to selection of 
specific candidates and their subsequent evaluation as DNA vaccines against brucellosis. 
Various candidates have been explored for their value as DNA vaccines against brucellosis 
providing various levels of protective efficacy in the mouse model (108, 111, 114, 113, 112). 
Disadvantages of the DNA vaccination approach are the amount of DNA required to elicit 
the required response, and the often disappointing results obtained following assessment of 
the vaccines in the target animal (118). Investigation of enhanced delivery mechanisms may 
overcome these issues. 
The availability of the genome sequences and the application of postgenomic approaches to 
identify potential vaccine candidate antigens, together with the improving knowledge of the 
protective immune response would provide an efficient nonliving vaccine.  
13. Conclusion 
Brucellosis is a disease which causes economic disadvantages in developed as well as 
developing/ underdeveloped countries. However to overcome such economic disaster, it is 
essential by employing various techniques ranging from conventional techniques to 
advanced ones such as genetic , proteomics, metabolic engineering. However by employing 
such techniques it will be possible to develop a vaccine against Brucellosis either for animals 
or humans. 
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